What are the newest approved medications for Restless Legs Syndrome and their recommended dosing?

Best Medications for Restless Legs Syndrome

Based on the most recent 2025 AASM guidelines, gabapentin enacarbil, gabapentin, and pregabalin are the strongest first-line medication recommendations for RLS, with IV ferric carboxymaltose as the top iron formulation—all receiving strong recommendations with moderate certainty of evidence. 1

First-Line Pharmacological Treatments (Strong Recommendations)

The 2025 AASM guidelines represent a major paradigm shift away from dopamine agonists. The following medications receive strong recommendations (meaning clinicians should follow under most circumstances):

Alpha-2-Delta Calcium Channel Ligands (Preferred First-Line)

1. Gabapentin enacarbil - Strong recommendation, moderate certainty 1

   • This is the only FDA-approved non-dopaminergic medication for RLS
   • Superior bioavailability compared to regular gabapentin 2
   • Critical advantage: No augmentation risk (unlike dopamine agonists)

2. Gabapentin - Strong recommendation, moderate certainty 1

   • Equally strong recommendation as gabapentin enacarbil
   • More widely available globally

3. Pregabalin - Strong recommendation, moderate certainty 1

   • Same strength of recommendation as the gabapentin formulations

Intravenous Iron (For Appropriate Iron Status)

1. IV ferric carboxymaltose - Strong recommendation, moderate certainty 1
   • Check iron parameters first (ferritin and transferrin saturation)
   • This is the only IV iron formulation with a strong recommendation
   • Other IV iron options (low molecular weight iron dextran, ferumoxytol) receive only conditional recommendations 1

Second-Line Options (Conditional Recommendations)

When first-line treatments fail or are not tolerated:

Oral Iron

• Ferrous sulfate - Conditional recommendation, moderate certainty 1
• Must verify appropriate iron status before use

Opioids

• Extended-release oxycodone and other opioids - Conditional recommendation, moderate certainty 1
• Reserve for refractory cases or when first-line agents fail 3

Novel Option

• Dipyridamole (adenosinergic agent) - Conditional recommendation, low certainty 1
• However, the World Sleep Society does NOT support this recommendation 4

Critical Medications to AVOID

Strong Recommendation AGAINST:

• Cabergoline - Strong recommendation against, moderate certainty 1

Conditional Recommendations AGAINST (Standard Use):

The guidelines now suggest against standard use of all dopamine agonists due to augmentation risk:

• Pramipexole - Conditional recommendation against standard use 1
• Ropinirole - Conditional recommendation against standard use 1
• Rotigotine (transdermal) - Conditional recommendation against standard use 1
• Levodopa - Conditional recommendation against standard use 1

Important caveat: These dopaminergic agents may still be used short-term in patients who prioritize immediate symptom relief over long-term augmentation risk, but this is explicitly NOT the standard approach 1

Also Avoid:

• Bupropion, carbamazepine, clonazepam, valproic acid, valerian 1

Clinical Algorithm

Step 1: Address exacerbating factors

• Discontinue alcohol, caffeine, antihistamines, serotonergic/antidopaminergic medications
• Treat obstructive sleep apnea if present 1

Step 2: Check iron parameters

• Measure ferritin and transferrin saturation
• If deficient/low-normal, start with IV ferric carboxymaltose (strong recommendation) or oral ferrous sulfate (conditional recommendation) 1

Step 3: Initiate alpha-2-delta ligand

• Choose gabapentin enacarbil, gabapentin, OR pregabalin
• All three have equal strength of recommendation 1
• Selection based on availability and cost (gabapentin enacarbil less available globally 4, 5)

Step 4: If refractory to Step 3

• Consider adding or switching to extended-release oxycodone or other opioids 1
• Combination therapy may be necessary 3

Step 5: If patient is already on dopamine agonist with augmentation

• Add alpha-2-delta ligand or opioid FIRST
• Once adequate symptom control achieved, very slowly taper and discontinue the dopamine agonist 3
• Never abruptly stop dopamine agonists - causes severe rebound RLS and insomnia 3

Key Pitfalls to Avoid

1. Do not start with dopamine agonists - The 2025 guidelines represent a complete reversal from previous practice. While these medications work short-term, augmentation (iatrogenic worsening) occurs commonly and creates long-term management problems 1, 3

2. Do not abruptly switch from dopamine agonist to alternative - If patient already on DA with augmentation, add the new agent first, achieve symptom control, then very slowly taper DA 3

3. Do not use dipyridamole as standard practice - Despite AASM conditional recommendation, the World Sleep Society does not support this due to limited global evidence 4

4. Do not forget iron status - Always check before initiating other treatments, as iron deficiency is a reversible cause 1

Special Populations

End-Stage Renal Disease (ESRD)

• Gabapentin - conditional recommendation 1
• IV iron sucrose if ferritin <200 ng/mL and transferrin saturation <20% - conditional recommendation 1
• Vitamin C - conditional recommendation 1

Pregnancy

• Consider pregnancy-specific safety profile of each treatment 1
• Limited pharmacological options available

Children

• Ferrous sulfate with appropriate iron status - conditional recommendation 1

The 2025 AASM guidelines mark a fundamental shift toward alpha-2-delta ligands and away from dopamine agonists as standard RLS treatment, prioritizing long-term quality of life over short-term symptom relief 1, 4.